These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10735497)

  • 1. The value of rapid functional assays of germline p53 status in LFS and LFL families.
    Camplejohn RS; Sodha N; Gilchrist R; Lomax ME; Duddy PM; Miner C; Alarcon-Gonzalez P; Barnes DM; Eeles RA
    Br J Cancer; 2000 Mar; 82(6):1145-8. PubMed ID: 10735497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
    Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
    Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
    Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
    Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
    Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN
    J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
    Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
    Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
    Bendig I; Mohr N; Kramer F; Weber BH
    Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
    Nichols KE; Malkin D; Garber JE; Fraumeni JF; Li FP
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):83-7. PubMed ID: 11219776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The mutational spectra of gene p53 in different types of tumors].
    Glazko GV; Rogozin IB; Sozinov AA
    Tsitol Genet; 1999; 33(3):14-20. PubMed ID: 10474858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
    Kouidou S; Malousi A; Maglaveras N
    Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors.
    Smardová J
    Neoplasma; 1999; 46(2):80-8. PubMed ID: 10466430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
    Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
    J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
    Pötzsch C; Voigtländer T; Lübbert M
    J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.
    Krutilkova V; Trkova M; Fleitz J; Gregor V; Novotna K; Krepelova A; Sumerauer D; Kodet R; Siruckova S; Plevova P; Bendova S; Hedvicakova P; Foreman NK; Sedlacek Z
    Eur J Cancer; 2005 Jul; 41(11):1597-603. PubMed ID: 15925506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for germline p53 mutations in pediatric and adult patients of high-risk groups in Poland.
    Fiszer-Maliszewska L; Czernik J; Sawicz-Birkowska K; Perek D; Kozera M; Wojciechowska B; Kazanowska B; Hudziec P; Kilar E
    Arch Immunol Ther Exp (Warsz); 2000; 48(4):309-15. PubMed ID: 11059649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
    Wu CC; Shete S; Amos CI; Strong LC
    Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value.
    Shi XB; Gandour-Edwards R; Beckett LA; Deitch AD; de Vere White RW
    BJU Int; 2004 Nov; 94(7):996-1002. PubMed ID: 15541116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
    Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
    J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.